Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy - PubMed (original) (raw)

W Kelsey, M Lechin, G Zhao, Q T Yu, W Zoghbi, M Quinones, E Elstein, A Omran, H Rakowski, D Wigle, C C Liew, M Sole, R Roberts, A J Marian

Affiliations

PMID: 9444881

Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy

R Brugada et al. J Investig Med. 1997 Dec.

Abstract

Background: The phenotypic expression of left ventricular hypertrophy (LVH) in patients with hypertrophic cardiomyopathy (HCM) is variable. This phenotypic variability is not completely explained by the responsible mutations or other known factors. Recent data denote a role for the modifier genes and environmental factors. We studied the role of 3 potential modifier genes, i.e., angiotensinogen (AGT), angiotensin II receptor 1a (AT1a), and endothelin-1 (END1) on the phenotypic expression of LVH in patients with hypertrophic cardiomyopathy (HCM).

Methods: The study population was comprised of 108 genetically independent patients with HCM. Left ventricular mass index (LVMI) and LVH score were determined per published protocols. The genotypes of AGT (M235T, T174M, and G-6A), AT1a, and END1 were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or mutation-specific PCR (MS-PCR).

Results: Male patients had higher mean LVMI and LVH score than female patients (146.0 +/- 33.5 vs 129.4 +/- 33.6, p = 0.01 and 6.0 vs 5.0, p = 0.010, respectively). Gender accounted for 4.8% and 5.4% of the variability of LVMI and LVH score, respectively. The END1 genotypes also had a significant influence on LVH scores accounting for 2.9% of their variability (p = 0.042). The median LVH score was greater in patients with the AA and AG genotypes, as compared to patients with the GG genotype (7.0 vs 5.0, p = 0.034). Neither the AGT nor the AT1 genotypes had a significant influence on the expression of LVH. In multivariate regression analysis, END1 and gender accounted for 7.3% of the variability of the LVH score (p = 0.007).

Conclusions: Our results show that gender and the END1 gene modify the phenotypic expression of hypertrophy in patients with HCM.

PubMed Disclaimer

Cited by

Modifier genes for hypertrophic cardiomyopathy.
Marian AJ. Marian AJ. Curr Opin Cardiol. 2002 May;17(3):242-52. doi: 10.1097/01.HCO.0000013803.40803.6A. Curr Opin Cardiol. 2002. PMID: 12015473 Free PMC article. Review.
Molecular genetics and pathogenesis of hypertrophic cardiomyopathy.
Marian AJ, Salek L, Lutucuta S. Marian AJ, et al. Minerva Med. 2001 Dec;92(6):435-51. Minerva Med. 2001. PMID: 11740432 Free PMC article. Review.
Hypertrophic cardiomyopathy: from genetics to treatment.
Marian AJ. Marian AJ. Eur J Clin Invest. 2010 Apr;40(4):360-9. doi: 10.1111/j.1365-2362.2010.02268.x. Eur J Clin Invest. 2010. PMID: 20503496 Free PMC article. Review.
The molecular genetic basis for hypertrophic cardiomyopathy.
Marian AJ, Roberts R. Marian AJ, et al. J Mol Cell Cardiol. 2001 Apr;33(4):655-70. doi: 10.1006/jmcc.2001.1340. J Mol Cell Cardiol. 2001. PMID: 11273720 Free PMC article. Review.
Contemporary treatment of hypertrophic cardiomyopathy.
Marian AJ. Marian AJ. Tex Heart Inst J. 2009;36(3):194-204. Tex Heart Inst J. 2009. PMID: 19568388 Free PMC article. Review. No abstract available.

Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy - PubMed (original) (raw)